MAYNE Pharma’s proposed
$800-million plus US acquisition of
a portfolio of generics (PD 28 Jun)
could see the company catapulted
into the top 100 publicly listed
companies in Australia.
The move is likely to attract
increased institutional investment,
according to Fairfax Media, with
the deal seeing Mayne’s share price
surge almost 29% last week, while
the equity raising to fund the deal
likely to lift its capitalisation to as
much as $3 billion.
The 42 generics being acquired
from Teva and Allergan have an
average profit margin around
50% which is more than twice
Mayne’s current margin levels
and also opens the company
up to new markets such as oral
contraceptives.
Analysts are reported to say that
the higher margins will raise cash
flow and go towards eliminating
most of the group’s debt over the
next 18 months or so.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jul 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jul 16
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.